| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Autism spectrum disorder (ASD) is one of the most common neurodevelopmental disorders. The diagnosis for ASD is often challenging because these diagnostic approaches are less objective and time consuming. Thus, an appropriate diagnosis needs to consider the applicability of the diagnostic approach. We measured the levels of kynurenine pathway(KP) metabolites in the serum of ASD models mice to assess the potential of KP metabolites as predictive peripheral biomarkers for neurodevelopmental disorders. We found genetical ASD model mice showed drastic changes in KP metabolite concentrations. We also found maternal inflammation dramatically changed KP metabolites in maternal serum, pointing to the ability of kynurenine to cross the placenta and change the KP metabolites which are affected as neuroactive compounds in the fetal brain. Our results suggested that KP metabolites are potential diagnostic biomarkers for neurodevelopmental disorders.
|
